

1 **Title**

4 **Nucleolar detention of NONO shields DNA double-strand breaks from
5 aberrant transcripts**

9 **Authors**

10 Barbara Trifault^{1,2}, Victoria Mamontova^{1,2}, Giacomo Cossa², Sabina Ganskikh³, Yuanjie Wei³,
11 Julia Hofstetter⁴, Pranjali Bhandare⁴, Apoorva Baluapuri^{4,5}, Daniel Solvie², Carsten P. Ade²,
12 Peter Gallant², Elmar Wolf⁴, Mathias Munschauer³, Kaspar Burger^{1,2,6*}

14 **Affiliations**

15 ¹Mildred Scheel Early Career Center for Cancer Research, University Hospital Würzburg,
16 Germany.

17 ²Department of Biochemistry and Molecular Biology, Biocenter of the University of Würzburg,
18 Germany.

19 ³Helmholtz Institute for RNA-based Infection Research, Helmholtz-Center for Infection
20 Research, Germany.

21 ⁴Cancer Systems Biology Group, Biocenter, University of Würzburg, Germany.

22 ⁵Department of Biological Chemistry and Molecular Pharmacology, Blavatnik Institute, Harvard
23 Medical School, Boston, MA, USA.

24 ⁶Lead contact.

26 *Correspondence: kaspar.burger@uni-wuerzburg.de

28 **Short title:** NONO couples the nucleolus to DNA repair

30 **ABSTRACT**

31 RNA-binding proteins (RBPs) stimulate the DNA damage response (DDR). The RBP NONO
32 marks nuclear paraspeckles in unperturbed cells and undergoes poorly understood re-localisation
33 to the nucleolus upon induction of DNA double-strand breaks (DSBs). Here we show that treatment
34 with the topoisomerase-II inhibitor etoposide stimulates the production of RNA polymerase II-
35 dependent, DNA damage-induced nucleolar antisense RNAs (diNARs) in human cells. diNARs
36 originate from the nucleolar intergenic spacer and tether NONO to the nucleolus via its RRM1
37 domain. NONO occupancy at protein-coding gene promoters is reduced by etoposide, which
38 attenuates pre-mRNA synthesis, enhances NONO binding to pre-mRNA transcripts and is
39 accompanied by nucleolar detention of such transcripts. The depletion or mutation of NONO
40 interferes with detention and prolongs DSB signaling. Together, we describe a nucleolar DDR
41 pathway that shields NONO and aberrant transcripts from DSBs to promote DNA repair.

42

43 **Keywords**

44 NONO; nucleolus; RNA polymerase II; DNA double-strand break repair; non-coding RNA.

45

46 **Introduction**

47 Genome stability requires the faithful inheritance of genetic information. The DNA damage
48 response (DDR) recognizes and repairs DNA lesions to maintain genome stability(Jackson and
49 Bartek 2009; Ciccia and Elledge 2010). Kinases like *Ataxia-telangiectasia mutated* (ATM) inhibit
50 unscheduled RNA synthesis to suppress DNA double-strand breaks (DSBs) and promote DSB
51 repair (DSBR) (Blackford and Jackson 2017; Machour and Ayoub 2020). However, transcripts and
52 RNA-binding proteins (RBPs) emerge as regulators of the DDR an also stimulate DSBR (Duterte
53 et al. 2014; Michelini et al. 2018; Burger et al. 2019; Zong et al. 2020). The *Drosophila*
54 behavior/human splicing (DBHS) protein family member NONO associates with actively
55 transcribed chromatin and paraspeckles in unperturbed cells, and participates in DSBR, for
56 instance by stimulating non-homologous end joining (Shav-Tal and Zipori 2002; Krietsch et al.
57 2012; Knott et al. 2016; Jaafar et al. 2017; Wang et al. 2022). Interestingly, NONO accumulates in
58 condensates induced by transcription inhibition to suppress gene fusions, but also undergoes poorly
59 understood re-localisation to the nucleolus upon DNA damage (Moore et al. 2011; Yasuhara et al.
60 2022).

61 Here we show that the topoisomerase-II inhibitor etoposide stimulates a nucleolar DDR
62 pathway, which involves RNA polymerase II (RNAPII)-dependent, DNA damage-induced
63 nucleolar antisense RNAs (diNARs) that form nucleolar DNA-RNA-hybrids (R-loops) and deplete
64 NONO from protein-coding gene promoters, which reduces pre-mRNA synthesis, detains aberrant
65 transcripts and stimulates DSBR.

66

67 **Results**

68 **The RRM1 domain facilitates NONO nucleolar re-localisation**

69 We showed previously that treatment with etoposide enriches NONO in non-disintegrated nucleoli
70 (Trifault et al. 2022) and confirmed this by costaining of DBHS proteins NONO, SFPQ or PSPC1
71 with nucleophosmin (NPM1) (Supplemental Fig. S1A,B). Etoposide treatment increased the ser-
72 139 phosphorylated histone H2.X variant (γ H2A.X) >5-fold, but not DBHS proteins (Supplemental
73 Fig. S1C). Next, we tested if NONO re-localisation is induced by nucleolar DSBs. We employed
74 the 4-hydroxytamoxifen (4-OHT)-inducible endonucleases I-PpoI, which cleaves 28S ribosomal
75 (r)DNA (van Sluis and McStay 2019). We observed signals for γ H2A.X and 53BP1, but not NONO
76 around disintegrated nucleoli upon 4-OHT treatment (Supplemental Fig. S2A,B), suggesting that
77 nucleoplasmic DSBs trigger NONO nucleolar re-localisation. NONO RNA recognition motifs 1/2
78 (RRM1/2) mediate binding to nucleic acids (Knott et al. 2016). To test, which domain confers
79 nucleolar re-localisation, we created HA-NONO mutants (Supplemental Fig. S2C), monitored their
80 expression (Supplemental Fig. S2D), and assessed their localisation (Fig. 1A, Supplemental Fig.
81 S2E). Costaining of mutants with fibrillarin revealed that full length (FL) HA-NONO, the RRM1
82 deletion mutant (Δ RRM1) and the carboxy-terminal deletion mutant (Δ C-ter) localised in the
83 nucleoplasm in unperturbed cells. Upon incubation with etoposide, FL and Δ C-ter displayed pan-
84 nuclear localisation and co-staining with fibrillarin, which was impaired by Δ RRM1. Thus, NONO
85 RRM1 confers nucleolar re-localisation.

86

87 **RNAPII produces DNA damage-induced nucleolar transcripts at distinct IGS loci**

88 Non-ribosomal, nucleolar transcripts maintain homeostasis by sequestration of RBPs (Mamontova
89 et al. 2021; Feng and Manley 2022). Intriguingly, carboxy-terminal domain ser-2 phosphorylated
90 RNA polymerase II (CTD S2P) synthesises antisense intergenic ncRNA (asincRNA) on nucleolar
91 chromatin to regulate RNA polymerase I (RNAPI) in unperturbed cells (Abraham et al. 2020). We
92 hypothesised that the DDR modulates nucleolar RNAPII activity and applied mammalian nascent

93 elongation transcript sequencing (mNET-seq) to profile RNAPII-associated transcripts. First, we
94 confirmed enrichment of RNAPII and associated transcripts upon immunoselection (Supplemental
95 Fig. S3A). mNET-seq revealed that etoposide treatment elevated CTD S2P mNET-seq reads for
96 about 25% of the 214 individually mapped intergenic spacer (IGS) sequences 2-3-fold, which we
97 termed DNA damage-induced nucleolar antisense RNAs (diNARs) (Fig. 1B,C). Pair-wise
98 comparison further suggested a locus-specific increase in diNARs at IGS loci 22, 30 and 38
99 (Supplemental Fig. S3B), which was also visualised on browser tracks (Fig. 1D, Supplemental Fig.
100 S3C-E). Next, we used chromatin immunoprecipitation (ChIP) to assess CTD S2P occupancy.
101 Treatment with etoposide, but not preincubation with the transcriptional kinase inhibitor THZ1,
102 elevated CTD S2P signals at IGS loci 22, 30 and 38 (Supplemental Fig. S3F). Importantly,
103 etoposide had little impact on CTD S2P marks (Supplemental Fig. S3G). Onset of antisense
104 transcripts was validated by RT-qPCR with antisense-specific forward primers (Supplemental Fig.
105 S3H). Next, we performed RNA-FISH to visualise prominently induced diNAR-IGS-22 and
106 observed an increased number of cells comprising nucleolar RNA-FISH signals upon etoposide
107 treatment (Fig. 1E, Supplemental Fig. S3I). We conclude that nucleolar CTD S2P produces
108 diNARs.

109

110 **diNARs form nucleolar R-loops to promote NONO re-localisation**

111 Nucleolar asincRNA form R-loops to shield RNAPI from the IGS (Abraham et al. 2020). As
112 asincRNA-coding IGS loci and diNAR-encoding regions overlap, we asked if nucleolar R-loops
113 mediate NONO nucleolar re-localisation. We used S9.6 and NONO antibodies in DNA-RNA
114 immunoprecipitation (DRIP) and NONO ChIP experiments. For S9.6 validation, we employed
115 U2OS DIVA cells, which express the 4-OHT-inducible endonuclease AsiSI to induce DSBs
116 (Clouaire et al. 2018). We assessed S9.6 reactivity at the R-loop-forming DS1 site (*RBMXL1*

117 promoter) (Clouaire et al. 2018). We detected DRIP signals at DS1 in the presence of 4-OHT,
118 which were sensitive to RNaseH digestion (Supplemental Fig. S4A). AsiSI cleavage was confirmed
119 by imaging of γ H2A.X and 53BP1 foci (Supplemental Fig. S4B). Next, we determined R-loop
120 levels on nucleolar chromatin (Fig. 2A). We found that etoposide increased DRIP signals across
121 the body of the IGS. To test if the formation of nucleolar R-loops correlates with elevated
122 occupancy of NONO on nucleolar chromatin we performed NONO ChIP assays. For validation,
123 we assessed NONO occupancy at DS1 in the absence or presence of NONO-targeting shRNA
124 (Supplemental Fig. S4C). NONO occupancy at DS1 was sensitive to NONO depletion
125 (Supplemental Fig. S4D). Next, we measured NONO occupancy on nucleolar chromatin. NONO
126 ChIP signals were detectable on rDNA, but not responsive to etoposide (Supplemental Fig. S4E).
127 On the IGS, however, NONO occupancy was modestly increased upon etoposide treatment, in
128 particular after two hours of chase and at regions that displayed increased levels of diNARs and R-
129 loops (Fig. 2B). To test if nucleolar R-loops promote NONO re-localisation, we overexpressed V5-
130 tagged RNaseH1 and imaged NONO localisation (Fig. 2C). The etoposide-induced nucleolar re-
131 localisation of NONO was impaired in cells that comparably express V5-RNaseH1 in the absence
132 or presence of etoposide (Supplemental Fig. S4F). The etoposide-induced accumulation of NONO
133 at IGS loci 22, 30, and 38 was also sensitive to overexpression of GFP-RNaseH1 (Fig. 2D). To
134 asses if NONO binds R-loop-forming IGS loci directly, we performed pull-down assays with
135 recombinant NONO (rec-NONO) and end-labeled DNA-RNA chimeras (gapmers). Gapmers were
136 designed with sequence complementary to diNAR-encoding region IGS-22, or IGS-20 control, to
137 mimic single-stranded DNA within R-loops. When incubating rec-NONO with immobilised
138 biotinylated gapmers, we found that gapmer-22 enriched rec-NONO >2-fold stronger than gapmer-
139 20 (Supplemental Fig. S4G). Next, we immobilised FL or Δ RRM1 HA-NONO variants on beads
140 and incubated them with radio-labeled gapmers (Fig. 2E, Supplemental Fig. S4H). Immobilised

141 FL, but not Δ RRM1, enriched gapmer-22 >2-fold stronger than gapmer-20. Thus, etoposide
142 induces nucleolar R-loops to promote NONO nucleolar re-localisation.

143

144 **DNA damage reduces NONO occupancy at protein-coding gene promoters and attenuates**
145 **pre-mRNA synthesis**

146 DSB signaling inhibits RNAPII activity, in particular close to transcriptional start sites (TSSs) and
147 NONO stimulates pre-mRNA synthesis in unperturbed cells (Iannelli et al. 2017; Wei et al. 2021).
148 Thus, we speculated that the etoposide-induced nucleolar re-localisation of NONO coincides with
149 reduced RNAPII activity on broken chromatin. To test this, we performed proximity ligation assays
150 (PLAs) for NONO and RNAPII or the elongation factor SPT5 and observed prominent PLA signals
151 for both costainings in unperturbed cells, which were sensitive to etoposide treatment (Fig. 3A).
152 Thus, we investigated if DNA damage alters NONO chromatin occupancy at protein-coding genes
153 and performed CUT&RUN-seq with the NONO antibody. We observed prominent binding of
154 NONO in a region from the TSS up to 1 kb downstream of the TSS, but not the TES of highly
155 expressed genes, which was markedly reduced upon etoposide treatment and sensitive to NONO
156 depletion (Fig. 3B,C, Supplemental Fig. S5A,B). We validated CUT&RUN-seq data by NONO
157 ChIP assays and detected NONO occupancy downstream of the TSSs of *ACTB* and *CCNB1*, which
158 was sensitive to etoposide treatment (Supplemental Fig. S5C). Next, we applied 4sU-seq to
159 measure nascent RNA synthesis. We found that etoposide treatment reduced the bulk of pre-mRNA
160 synthesis by ~25% within the gene body of highly expressed genes (Fig. 3D, Supplemental Fig.
161 S5D). The depletion of NONO *per se* reduced 4sU-seq reads to similar extent, but not further
162 reduced by combining NONO depletion with etoposide incubation. Thus, etoposide treatment
163 depletes NONO from the promoter-proximal region of some highly expressed genes to attenuate
164 RNAPII activity.

165

166 **NONO mediates the accumulation of pre-mRNA transcripts in the nucleolus**

167 NONO preferentially binds intron-containing transcripts in unperturbed cells (Xiao et al. 2019;
168 Zhang et al. 2022). We reasoned that the DDR shifts NONO from protein-coding chromatin to the
169 nucleolus to detain nascent transcripts from broken chromatin. To explore DNA damage-induced
170 NONO-dependent changes in the nucleolar transcriptome, we created U2OS cells that stably
171 express GFP-tagged ascorbate peroxidase 2 fused with three nucleolar targeting sequences from
172 the NF-κB-inducing kinase (U2OS:GFP-APEX2-NIK3), which can be used to map nucleolar
173 transcripts *in vivo* by proximity labeling and subsequent sequencing of immunoselected
174 biotinylated RNA (APEX-seq) (Fazal et al. 2019) (Fig. 4A). We confirmed GFP-APEX2-NIK3-
175 mediated biotinylation of nucleic acids by dot blotting (Supplemental Fig. S6A) and validated the
176 selective biotinylation of RNA on agarose gels by immunoselection and RNaseA digestion
177 (Supplemental Fig. S6B). We further confirmed nucleolar localisation and activity of the GFP-
178 APEX2-NIK3 reporter by costaining with NCL and a fluorescently labeled neutravidin probe,
179 irrespective of etoposide treatment (Supplemental Fig. S6C,D). Importantly, the expression of
180 GFP-APEX2-NIK3 did not interfere with NONO nucleolar re-localisation, nor did the depletion
181 of NONO interfere with GFP-APEX2-NIK3 localisation (Fig. 4B, Supplemental Fig. S6E).
182 Reassuringly, we found that proximity-mediated biotinylation by nucleolar GFP-APEX2-NIK3 in
183 the presence of etoposide increased the amount DBHS proteins, but not GFP-APEX2-NIK3 or
184 fibrillarin, that coimmunoprecipitate with streptavidin beads 2-4-fold (Fig. 4C). This prompted us
185 to perform APEX-seq in U2OS:GFP-APEX2-NIK3 cells. By assessing fold-changes for a total of
186 14463 intron-containing, biotin-labeled transcripts, we found 75 candidates with significantly
187 higher biotinylation upon etoposide treatment (Fig. 4D). To exclude that the changes in the levels
188 of biotinylated transcripts reflect lentiviral stress or perturbations upon biotin-phenol/H₂O₂

189 treatment, we compared the ratios of labeled transcripts from lentiviral transduced cells with rRNA-
190 depleted transcripts immunoselected from unlabeled and unperturbed controls. We found no
191 significant changes in the levels of biotinylated transcripts (Fig. 4E). To assess if the differential
192 biotinylation of transcripts depends on NONO, we repeated APEX-seq upon NONO depletion.
193 Strikingly, NONO depletion abolished the differential biotinylation, but not the synthesis of most
194 candidates (Fig. 4F, Supplemental Fig. S6F). To assess if NONO binds candidates differentially
195 upon DNA damage, we employed the NONO antibody for enhanced cross-linking
196 immunoprecipitation and sequencing (eCLIP-seq). We found that etoposide increased the total
197 number of NONO eCLIP-seq peaks from 2649 to 3991 and particularly enhanced NONO binding
198 to intron-containing transcripts, including the previously identified transcript DAZAP1 (Zhang et
199 al. 2022), and some of the identified APEX-seq candidates (CDKN1A, PURPL) (Fig. 4G,H,
200 Supplemental Fig. S6G,H). As NONO binding to chromatin-associated transcripts is strongly
201 correlated with the formation of R-loops (Wu et al. 2022), we tested if the defects in nucleolar
202 detention observed in NONO-deficient cells may be linked to aberrant R-loop levels. We expressed
203 the R-loop-stabilising V5-tagged RNaseH1 D210N mutant, or wild type control, and employed
204 CUT&RUN-seq to assess R-loops globally. We found that the depletion of NONO prior to
205 etoposide treatment increased the levels of R-loops within the gene body of APEX-seq candidates
206 CDKN1A and BTG2 (Fig. 4I, Supplemental Fig. S6I). This suggests that NONO mediates
207 nucleolar detention of pre-mRNA transcripts to mitigate R-loops level upon DNA damage.

208

209 **NONO inactivation impairs DSB signaling**

210 NONO depletion elevates R-loop levels at telomeres and promotes genome instability (Petti et al.
211 2019). To test the impact of NONO depletion on DSB signaling, we performed etoposide
212 incubation kinetics and detected defects in clearing ser-1981-phosphorylated (p)ATM and γH2A.X

213 upon NONO depletion (Supplemental Fig. S7A). Complementation with mCherry-NONO rescued
214 γ H2A.X levels partially (Supplemental Fig. S7B). To investigate if the DDR function of NONO
215 may be linked to its nucleolar re-localisation, we assessed the impact of RRM1 depletion on DSB
216 signaling. We found that overexpression of Δ RRM1, but not FL, increased phosphorylation of
217 DDR markers (Fig. 5A). Next, we asked if NONO depletion elevates the amount of DSBs and used
218 breaks labeling *in situ* and sequencing (BLISS-seq) to quantify DSBs (Fig. 5B). Indeed, NONO
219 depletion prior to etoposide treatment increased the amount of DSBs compared to non-depleted,
220 etoposide-treated cells at TSSs of highly expressed genes. For validation, we performed γ H2A.X
221 ChIP at the AsiSI-site DS1 (Supplemental Fig. S7C). Again, NONO depletion prior to 4-OHT
222 incubation increased γ H2A.X levels about 2-fold. Interestingly, histone H2B acetylation at lys-120
223 residues (H2BK120ac) functions as chromatin switch during DSBR at AsiSI sites (Clouaire et al.
224 2018). Thus, we applied CUT&RUN-seq to quantify the levels of H2BK120ac at TSSs of highly
225 expressed genes (Fig. 5C, Supplemental Fig. S7D). The depletion of NONO or etoposide treatment
226 alone modestly altered H2BK120ac levels at TSSs. Combining NONO depletion with etoposide
227 treatment, however, strongly increased the H2BK120ac mark. Finally, we rescued elevated
228 H2BK120ac levels by reexpression of mCherry-NONO (Supplemental Fig. S7E). We conclude
229 that NONO inactivation impairs DSB signaling.

230

231 **Discussion**

232 We describe NONO as attenuator of pre-mRNA synthesis and nucleolar detainer of nascent
233 transcripts to promote DSBR (Fig. 5D). Many RBPs display stress-induced nucleolar re-
234 localisation (Mamontova et al. 2021; Feng and Manley 2022). We provide evidence for diNAR-
235 induced nucleolar R-loops as anchor for nucleolar NONO. How is diNAR synthesis regulated? IGS
236 loci may become accessible for RNAPII upon DNA damage-induced looping of nucleolar DNA to

237 the nucleoplasm. Alternatively, RNAPII elongation factors may enrich in the nucleolus, as shown
238 for Spt4 in yeast (Yokoyama et al. 2023). Inhibition of RNAPI may also enhance diNAR synthesis.
239 DSB signaling indeed attenuates RNAPI transcription via ATM when DSBs occur both in the
240 nucleolus and the nucleoplasm (Korsholm et al. 2020; Li and Yan 2023). However, we did not
241 observe NONO nucleolar re-localisation upon induction of nucleolar DSBs with I-PpoI. This
242 suggests that the initial DNA-damaging events that trigger NONO re-localisation occur in the
243 nucleoplasm, but may also involve attenuation of RNAPI activity.

244 We observed a rapid decrease in NONO chromatin occupancy downstream of some protein-
245 coding gene promoters within 2 hours of etoposide treatment, whilst NONO accumulation at
246 nucleolar IGS loci was prominently detected upon chase. Thus, the reduction of NONO at promoter
247 regions likely precedes its re-localisation to nucleoli and impairs pre-mRNA synthesis as a
248 consequence thereof. Early studies identified NONO as transducer of cAMP signaling that interacts
249 with the CBP/p300 coactivator complex, copurifies with the mediator complex and associates with
250 the RNAPII CTD (Yang et al. 1997; Emili et al. 2002; Amelio et al. 2007). NONO enriches in
251 condensates to enhance the expression of pre-mRNA transcripts in neuroblastoma (Zhang et al.
252 2022). Other DBHS proteins also stabilise nascent pre-mRNA and favour the placement of
253 RNAPII-activating CTD phospho-marks at promoters (Shao et al. 2022). This suggests that DBHS
254 proteins foster RNAPII activity and that NONO nucleolar re-localisation diminishes RNAPII-
255 stimulating conditions.

256 NONO nucleolar re-localisation attenuates pre-mRNA synthesis to mitigate aberrant
257 transcripts via nucleolar shielding. This could promote R-loop-dependent DSBR pathway choice.
258 R-loops accumulate at actively transcribed DSBs (Bader and Bushell 2020). R-loops foster the
259 recruitment of critical homologous recombination factors to DSBs (Hatchi et al. 2015;
260 D'Alessandro et al. 2018). R-loops also promote DNA end resection via DNA endonuclease CtIP,

261 a critical step in DSBR pathway choice (Gómez-Cabello et al. 2022). Thus, the NONO-mediated
262 nucleolar detention of transcripts may suppress R-loops and, at least in part, explain promotion of
263 NHEJ by NONO (Krietsch et al. 2012; Jaafar et al. 2017). Overall, we provide evidence for a
264 nucleolar DDR that engages NONO to shield aberrant transcripts from DSBs.

265

266 **Materials and methods**

267 **Tissue culture**

268 Human U2OS, AsiSI-ER expressing U2OS (gift from Gaelle Legube), GFP-APEX2-NIK3
269 expressing U2OS (U2OS:GFP-APEX2-NIK3) and HEK293 cells were cultured in Dulbecco's
270 modified eagle's medium (DMEM, Gibco) with 10% fetal bovine serum (FBS, Capricorn), 100
271 U/mL penicillin-streptomycin (Gibco), 2 mM L-glutamine (Gibco) at 37°C and 5% CO₂. Cells
272 were incubated with etoposide (Sigma, 20 µM), THZ1 (Biozol, 1 µM), CX-5461 (Selleckchem, 1
273 µM), for 2 h, 4-OHT (Sigma, 10 µM) for 4 h, unless stated differently.

274

275 **Transfection and viral work**

276 Transfection of expression plasmids (Supplemental Table S1) was performed with Lipofectamine
277 2000 (Invitrogen) and Opti-MEM (Gibco) using the manufacturer's protocol. HA-NONO mutants
278 were PCR-cloned with primers (Supplemental Table S2) and a Q5 site-directed mutagenesis kit
279 (NEB) using the manufacturer's protocol and verified by sequencing. siRNA (100 nM) was
280 transfected (6 h) on two consecutive days. Short-hairpin (sh)RNA were transduced by lentiviral
281 infection (Supplemental Table S2). To generate U2OS:GFP-APEX2-NIK3 cells, 10 µg pLX304-
282 GFP-APEX2-NIK3 plasmid (gift from Alice Ting) was pooled with psPAX2 and pMD2.G (gift
283 from Elmar Wolf), mixed with 30 µL polyethylenimine (Calbiochem), mixed in 500 µL OptiMEM,
284 incubated (25 min, RT), added to HEK293 cells preincubated in 5 mL DMEM/2% FBS, and

285 transfected (8 h). Virus was harvested, sterile filtered and frozen. U2OS cells were infected (24 h)
286 in viral mixture (1.5 mL DMEM, 1.5 mL viral harvest, 6 μ L polybrene, Invitrogen) and DMEM
287 with 7.5 μ g/mL blasticidin (Sigma) for polyclonal selection (10 days).

288

289 **Protein analytics**

290 Proteins were assessed as whole cell extracts, directly lysed, boiled and sonicated in 4x sample
291 buffer (250 mM tris-HCl pH6.8, 8% SDS, 40% glycerol, 8% β -mercaptoethanol, 0.02%
292 bromophenol blue). Samples were separated by SDS-PAGE and stained with a SilverQuest kit
293 (Invitrogen) or transferred to nitrocellulose membranes (Cytivia), blocked and washed in
294 PBS/0.1% triton x-100/5% milk (PBST), probed with selective antibodies (Supplemental Table
295 S3) and visualised with an ECL kit (Cytivia) on an imaging station (LAS-4000, Fuji). Signals were
296 quantified by ImageJ (NIH). For immunoprecipitation (IP), cells were trypsinised, washed in PBS
297 and centrifuged (1200 rpm, 5 min). Pellets were lysed (10 min on ice) in 5 volumes IP buffer (200
298 mM NaCl, 0.5 mM EDTA, 20 mM HEPES, 0.2% NP-40, 10% glycerol, 400U Ribolock inhibitor,
299 1x protease/phosphatase inhibitor, Roche). Lysates were centrifuged (12000 rpm, 12 min) and
300 supernatants were incubated (2 h, 4°C) with 5 μ g antibodies conjugated to 25 μ L protein G
301 dynabeads (Invitrogen). Samples were immobilised, washed in IP buffer (10 min, 4°C) and eluted
302 with sample buffer (5 min, 95°C).

303

304 **Pull-down assays**

305 100 pmol gapmers (Supplemental Table S4) were labeled with biotin-16-ddUTP (Jena) and a 2nd
306 generation DIG-oligonucleotide 3'end-labeling kit (Roche) using the manufacturer's protocol or
307 with radioactive labeling mix (1 μ L 10x PNK buffer, NEB, 1 μ L of 100 μ M gapmer, 1 μ L T4 PNK,
308 NEB, 1 μ L γ -³²P-ATP, Hartmann, 6 μ L ddH₂O) for 40 min at 37°C. End-labeled gapmers were

309 centrifuged (3200 rpm, 5 min) with G-25 columns (Cytivia), diluted in 800 μ L IP buffer and
310 incubated (2 h, RT with rotation) with either 0.4 μ g recombinant NONO (rec-NONO)
311 (ActiveMotif) or HA-NONO variants that were immobilised on HA-conjugated protein G
312 dynabeads upon expression in HEK293 cells and IP. Rec-NONO complexes were captured on 25
313 μ L streptavidin C1 dynabeads (Invitrogen), washed in IP buffer, eluted by boiling (95°C, 5 min)
314 in sample buffer and analysed by immunoblotting. HA-NONO complexes were washed in IP
315 buffer, split and either eluted as above or by heating (65°C, 5 min) in 2x loading dye (7 M urea,
316 0.05% xylene cyanol, 0.05% bromophenol blue) for separation by UREA-PAGE (30 min, 350 V)
317 in 1x TBE buffer (90 mM tris, 90 mM boric acid, 2 mM EDTA), transfer on whatman paper with
318 a gel-dryer (BioRad) and detection by autoradiography and films (Cytivia).

319

320 **BLISS-seq**

321 Cells were washed in PBS, fixed (10 min, RT) with 5% paraformaldehyde, washed with PBS, lysed
322 (1 h, 4°C) in lysis buffer 1 (10 mM tris-HCl pH8.0, 10 mM NaCl, 1 mM EDTA, 0.2% triton x-
323 100), washed in PBS, lysed again (1 h, 37°C) in lysis buffer 2 (10 mM tris-HCl pH8.0, 150 mM
324 NaCl, 1 mM EDTA, 0.3% SDS) and washed in PBS. For AsiSI digestion, samples were
325 equilibrated (2 min, RT) in 150 μ L CutSmart buffer (NEB). 3 μ l recombinant AsiSI endonuclease
326 (10U/ μ L, NEB) was added to three biological replicates and incubated (2 h, 37°C). Controls were
327 incubated in buffer only. For DSB blunting, samples were washed in CutSmart buffer, and
328 incubated (1h, RT) in 150 μ L blunting mix (112.5 μ L ddH₂O, 15 μ L 10x blunting buffer, NEB, 15
329 μ L 100 μ M dNTPs, 0.3 μ L 50 mg/mL BSA, 6 μ L blunting enzyme mix from quick blunting kit,
330 NEB). Prior to ligation, 10 μ M of corresponding BLISS adapters (Supplemental Table S5) were
331 mixed equimolar and annealed (5 min, 95°C with gradient cooling to 25°C). For ligation, samples
332 were washed in CutSmart buffer, preincubated (5 min, RT) in 1x T4 ligase buffer (NEB), and

333 incubated (18 h, 16°C with gentle shaking) in 150 μ L ligation buffer (124.5 μ L ddH₂O, 15 μ L 10x
334 T4 ligase buffer, 3 μ L 50 mg/mL BSA, 1.5 μ L 2000U/ μ L T4 ligase, NEB, 6 μ L BLISS adapter
335 pairs). For removal of excess adapters, samples were incubated (1 h, 37°C, with gentle shaking) in
336 high salt wash buffer (10 mM tris-HCl pH8.0, 2 M NaCl, 2 mM EDTA, 0.5% triton x-100) and
337 washed in PBS. For extraction of genomic DNA, samples were incubated (5 min, RT) in 100 μ L
338 extraction buffer (10 mM tris-HCl pH8.0, 100 mM NaCl, 50 mM EDTA, 1% SDS, 10% 10 mg/mL
339 proteinase K, Sigma), harvested by scaping, pooled (merged conditions for each replicate), and
340 incubated (18 h, 55°C). DNA was purified by phenol/chloroform extraction, recovered in 50 μ L
341 ddH₂O, and sonicated (Covaris). Fragmented DNA was concentrated with SPRI select beads
342 (Beckman) and a magnet (Alpaqua), washed with 80% ethanol, air-dried and eluted in 8 μ L ddH₂O.
343 For in vitro transcription (IVT), 7.5 μ L DNA was incubated (14 h, 37°C) with IVT mix (0.5 μ L
344 Ribolock inhibitor, Invitrogen, 2 μ L T7 polymerase buffer, NEB, 8 μ L rNTP mix, 2 μ L T7
345 polymerase, Invitrogen). DNA was removed by addition of 1 μ L turbo DNase (Invitrogen) for 15
346 min. RNA size selection and clean-up was performed with RNAClean XP beads (Beckman), size
347 selected RNA was washed in 80% ethanol, air-dried and eluted in 6 μ L ddH₂O. For library
348 preparation, 1 μ L of 5 μ M RA3 adapter (NEB) was added to 5 μ L RNA sample, incubated (2 min,
349 70°C) and placed on ice. 4 μ L ligation mix (2 μ L 10x T4 ligase buffer, NEB, 1 μ L T4 RNA ligase
350 2, truncated, NEB, 1 μ L Ribolock inhibitor) was added and incubated (1 h, 28°C). For reverse
351 transcription (RT), 3.5 μ L ddH₂O and 1 μ L 10 μ M RTP primer (NEB) was added, incubated (2
352 min, 70°C) and placed on ice. 5.5 μ L RT mix (2 μ L 5xGC buffer, Invitrogen, 0.5 μ L 12.5 mM
353 dNTP mix, 1 μ L 100 mM DTT, 1 μ L SuperScriptIII reverse transcriptase, Invitrogen, 1 μ L
354 Ribolock inhibitor) was added and incubated (1 h, 50°C) and heat inactivated (15 min, 70°C). For
355 indexing and amplification, 10 μ L of RT reaction was mixed with 25 μ L NEBNext 2x PCR mix,
356 2 μ L 10 μ M RPI primer (NEB), 2 μ L 10 μ M RP1 primer (NEB), 1 μ L ddH₂O and PCR amplified

357 for 16-18 cycles. Library clean-up, was performed with AMPure XP beads (Beckman). The library
358 was captured, washed with 80% ethanol, air-dried, eluted in 20 μ L ddH₂O prior to sequencing.

359

360 **ChIP and CUT&RUN-seq**

361 For ChIP, cells were fixed with 1% formaldehyde (10 min, 37°C), quenched in 0.125 M glycine
362 (10 min, 37°C), washed in PBS and centrifuged (2000 rpm, 5 min). Pellets were resuspended in
363 500 μ L cold cell lysis buffer (5 mM PIPES pH8.0, 85 mM KCl, 0.5% NP-40, 1x
364 protease/phosphatase inhibitor) and lysed (10 min on ice). Nuclei were centrifuged (3000 rpm, 5
365 min) and resuspended in 400 μ L cold nuclear lysis buffer (1% SDS, 10 mM EDTA, 50 mM tris-
366 HCl pH8.0, 1x protease/phosphatase inhibitor) and lysed (10 min on ice). Lysates were sonicated
367 (5x 5 min, 30 sec on/off) with a Bioruptor (Diagenode) and pelleted (13000 rpm, 10 min). The
368 supernatant was mixed with 2 mL dilution buffer (0.01% SDS, 1.1% triton x-100, 1.2 mM EDTA,
369 16.7 mM tris-HCl pH8.0, 167 mM NaCl, 1x protease/phosphatase inhibitor). Diluted samples were
370 aliquoted, 5 μ g antibodies were added (IP sample) or not (input) and incubated overnight (4°C with
371 rotation). For pull-down, 20 μ L of protein G dynabeads were added to IP samples, incubated (1.5
372 h with rotation), immobilised and washed in wash buffer A (0.1% SDS, 1% triton x-100, 2 mM
373 EDTA, 20 mM tris-HCl pH8.0, 150 mM NaCl), B (0.1% SDS, 1% triton x-100, 2 mM EDTA, 20
374 mM tris-HCl pH8.0, 500 mM NaCl), C (0.25 M LiCl, 1% NP-40, 1% sodium deoxycholate, 1 mM
375 EDTA and 10 mM tris-HCl pH8.0), and twice with D (10 mM Tris-HCl pH8.0, 1 mM EDTA). For
376 elution, samples were incubated with 500 μ L elution buffer (1% SDS, 0.1 M NaHCO₃) for 30 min
377 with rotation. Reversal of cross-links was performed at 65°C overnight after adding 30 μ L 5 M
378 NaCl, 1 μ L 10 μ g/mL RNaseA (Sigma), 10 μ L 0.5 M EDTA, 20 μ L 1 M tris-HCl pH6.5, 2 μ L 10
379 mg/mL proteinase K (Sigma) to input and IP samples. DNA was purified by phenol/chloroform
380 extraction, recovered in ddH₂O, assessed by qPCR with selective primers (Supplemental Table S6).

381 For DNA-RNA hybrid IP (DRIP) non-crosslinked lysates were incubated (1 h, 37°C) with 10U
382 RNaseH (NEB) prior to immunoselection. For CUT&RUN-seq, cells were harvested with accutase
383 (Sigma), centrifuged (600 rpm, 3 min) and washed in wash buffer (20 mM HEPES pH7.5, 150 mM
384 NaCl, 0.5 mM spermidine). Cells were incubated (10 min, RT) with 10 µL concanavalinA-coated
385 magnetic beads (BioMag) resuspended in an equal volume of binding buffer (20 mM HEPES
386 pH7.5, 10 mM KCl, 1 mM CaCl₂, 1 mM MnCl₂), immobilised, permeabilised with 150 µL antibody
387 buffer (20 mM HEPES pH7.5, 150 mM NaCl, 0.5 mM spermidine, 0.05% digitonin, 2 mM EDTA)
388 and incubated with 1 µg primary antibody (800 rpm, 4°C, overnight with rotation). Samples were
389 immobilised, washed in dig-wash buffer (20 mM HEPES pH7.5, 150 mM NaCl, 0.5 mM
390 spermidine, 0.05% digitonin) and incubated (1 h, 800 rpm, 4°C with rotation) with 150 µL protein
391 A/G-MNase fusion protein (1 µg/mL, CST). Samples were immobilised, washed in dig-wash
392 buffer and once with 1 mL rinse buffer (20 mM HEPES pH7.5, 0.05% digitonin, 0.5 mM
393 spermidine). For chromatin digestion and release, samples were incubated (30 min, on ice) in cold
394 digestion buffer (3.5 mM HEPES pH7.5, 10 mM CaCl₂, 0.05% digitonin). The reaction was
395 stopped by addition of 200 µL stop buffer (170 mM NaCl, 20 mM EGTA, 0.05% digitonin, 50
396 µg/mL RNaseA, 25 µg/mL glycogen) and fragments were released by incubation (30 min, 37°C).
397 The supernatant was incubated (1 h, 50°C) with 2 µL 10% SDS and 5 µL proteinase K (10 mg/mL,
398 Sigma). Chromatin was recovered by phenol/chloroform extraction and resuspended in 30 µL TE
399 (1 mM tris-HCl pH8.0, 0.1 mM EDTA). For sequencing, three biological replicates were quantified
400 with a fragment analyser (Advanced Analytical), pooled and subjected to library preparation.
401 Libraries for small DNA fragments (25-75 bp) were prepared with NEBNext Ultra II DNA library
402 prep Kit (NEB#E7645).

403

404 **RNA analytics**

405 Total RNA was isolated by TRIzol (Invitrogen) using the manufacturer's protocol. cDNA was
406 synthesised with SuperScriptIII enzyme (Invitrogen) and gene-specific primers (Supplemental
407 Table S6) and quantified upon reverse transcription quantitative PCR (RT-qPCR) with PowerUp
408 SYBR green master mix (Applied) using the manufacturer's protocol. For dot blots, total RNA was
409 extracted by TRIzol, resuspended in ddH₂O with 0.02% methylene blue, heated (5 min, 72°C),
410 spotted on a nylon membrane (Cytivia), crosslinked (120 mJ/cm²) in a crosslinker (UVP), blocked
411 in PBS/0.1% triton x-100/0.5% SDS (20 min), washed in PBS/0.1% triton x-100 (20 min),
412 incubated (4°C, overnight) with a streptavidin-HRP probe (Invitrogen), washed in PBS/0.1% triton
413 x-100 (20 min), and visualised with an ECL kit (Cytivia). For SYBR gold (Invitrogen) staining,
414 immunoselected transcripts were on-bead digested (10 min, RT) with 2 µL 10 µg/mL RNaseA
415 (Sigma), separated by UREA-PAGE, stained with 1x SYBR gold diluted in 1x TBE (10 min in the
416 dark) and visualised on a transilluminator (Thermo).

417

418 **mNET-seq**

419 For mNET-IP, 5 µg antibodies were coupled to protein G dynabeads, washed and resuspended in
420 100 µL NET-2 buffer (50 mM tris-HCl pH7.4, 150 mM NaCl, 0.05% NP-40). Cells were harvested,
421 washed in PBS and lysed in hypotonic buffer (10 mM HEPES pH7.9, 60 mM KCl, 1.5 mM MgCl₂,
422 1 mM EDTA, 1 mM DTT, 0.075% NP-40, 400U Ribolock inhibitor, 1x protease/phosphatase
423 inhibitor) (10 min, 4°C with rotation). Nuclei were centrifuged (2 min, 1000 rpm), washed in
424 hypotonic buffer without NP-40 and resuspended in 125 µL cold NUN1 buffer (20 mM tris-HCl
425 pH7.9, 75 mM NaCl, 0.5 mM EDTA, 50% glycerol, 400U Ribolock inhibitor, 1x
426 protease/phosphatase inhibitor). 1.2 mL NUN2 buffer (20 mM HEPES-KOH pH7.6, 300 mM
427 NaCl, 0.2 mM EDTA, 7.5 mM MgCl₂, 1% NP-40, 1 M urea, 400U Ribolock inhibitor, 1x
428 protease/phosphatase inhibitor) was added and nuclei were incubated (on ice, 15 min) and

429 centrifuged (10 min, 16000 rpm). Non-soluble chromatin pellet was washed in 100 μ L 1x MNase
430 buffer (NEB), centrifuged and digested (2 min, 37°C with rotation) in 100 μ L MNase reaction mix
431 (87 μ L ddH₂O, 10 μ L 10x MNase buffer, NEB, 1 μ L 100x BSA, 2 μ L 2000 U/ μ L MNase, NEB).
432 Digests were centrifuged (5 min, 16000 rpm) and the supernatant was diluted with 10 volumes
433 NET-2 buffer. Conjugated antibodies were added and incubated (2 h, 4°C with rotation). Samples
434 were immobilised and washed in NET-2 buffer. For analysis of proteins, input and mNET-IP
435 samples were analysed by immunoblotting as above. For analysis of transcripts, 10% of mNET-IP
436 sample was subjected to TRIzol extraction and RT-qPCR or end-labeled on beads with radioactive
437 PNK labeling mix and analysed by autoradiography or monitored for enrichment by
438 immunoblotting. 90% of mNET-IP sample was end-labeled on beads with non-radioactive PNK
439 labeling mix, eluted and separated by UREA-PAGE along with inputs. A small RNA (<100 nts)
440 fraction was size-selected according to methylene blue migration. Slices were incubated (2 h, RT
441 with rotation) in 400 μ L elution buffer (1 M NaOAc, 1 mM EDTA), centrifuged (2 min, 13000
442 rpm). Supernatants containing eluted RNA were loaded on spin-x-columns (Coster) and
443 centrifuged (1 min, 13000 rpm). Flow-through was precipitated with 1 mL 100% ethanol and 1 μ L
444 glycogen (Invitrogen), incubated (20 min, RT) and centrifuged (20 min, 13000 rpm). Pellets were
445 washed in 70% ethanol, air-dried and recovered in 6 μ L ddH₂O. Three biological replicates were
446 pooled and subjected to library preparation. Libraries were prepared with NEBNext Multiplex
447 small RNA library prep Kit (NEB#7300) using the manufacturer's protocol.

448

449 **4sU-seq and APEX-seq**

450 For 4sU-tagging, cells were incubated with 4sU (Sigma, 2 mM) for 15 min, directly lysed in 2.1
451 mL QIAzol (Qiagen), spiked with 4sU-labeled mouse cell lysates, and total RNA was extracted
452 with miRNeasy kit (Qiagen) using the manufacturer's protocol. 50 μ g total RNA were diluted in

453 100 μ L ddH₂O, denatured (5 min, 65°C), put on ice (10 min) and incubated (2 h, RT) with 50 μ L
454 biotin-HPDP (Thermo, 1.85 mM) diluted in 100 μ L 2.5x biotin labeling buffer (25 mM tris-HCl
455 pH7.4, 2.5 mM EDTA). The reaction was mixed with an equal volume of chloroform/isoamyl
456 alcohol (24:1) and separated with a phase-lock tube (Qiagen) by centrifugation (14000 rpm, 5 min).
457 RNA was precipitated (5 min, RT) with 1 μ L glycogen (Invitrogen), 20 μ L 5 M NaCl and an equal
458 volume of isopropanol and centrifuged (14000 rpm, 20 min). The pellet was washed in an equal
459 volume of 75% ethanol, centrifuged (14000 rpm, 10 min) and resuspended in 100 μ L ddH₂O. For
460 APEX2-mediated proximity labeling, cells were incubated (30 min, 37°C) with 0.5 mM biotin-
461 phenol (Iris), pulsed (1 min) with 1 mM H₂O₂ (Sigma) and quenched by 10 mM sodium ascorbate
462 (Sigma), 5 mM trolox (Sigma) and 10 mM sodium azide (Sigma). Cells were directly lysed in 2.1
463 mL QIAzol (Qiagen) and total RNA was extracted with miRNeasy kit (Qiagen). For selection of
464 biotinylated transcripts, samples were incubated (15 min, RT) with 50 μ L streptavidin T1
465 dynabeads (Thermo), resuspended in an equal volume of 2x washing buffer (2 M NaCl, 10 mM
466 tris-HCl pH7.5, 1 mM EDTA, 0.1% tween-20). Samples were immobilised and washed in washing
467 buffer (1 M NaCl, 5 mM tris-HCl pH7.5, 0.5 mM EDTA, 0.05% tween-20). For elution, samples
468 were incubated with 100 μ L DTT (100 mM) at RT for 5 min and recovered by the RNeasy clean
469 up kit (Qiagen) using the manufacturer's protocol. For APEX-seq, biotinylated RNA was enriched
470 by incubation with 20 μ L streptavidin C1 dynabeads (2h, 4°C) washed in washing buffer (5 mM
471 tris-HCl, pH 7.5, 0.5 mM EDTA, 1 M NaCl; 0.1% TWEEN 20) and solution A (100 mM NaOH,
472 50 mM NaCl) and resuspended in solution B (100 mM NaCl). Samples were immobilised and
473 washed in washing buffer and resuspended in 54 μ L ddH₂O. For elution, samples were incubated
474 (1 h, 42°C followed by 1 h, 55°C) with 54 μ L 3x proteinase digestion buffer (330 μ L 10x PBS,
475 330 μ L 20% N-laurylsarcosine sodium solution, 66 μ L of 0.5 M EDTA, 16.5 μ L of 1 M DTT,
476 357.5 μ L ddH₂O, 10 μ L proteinase K, 2 μ L Ribolock) and recovered by RNA clean and

477 concentrator kit (Zymo) using the manufacturer's protocol. For 4sU-sequencing and APEX-seq,
478 samples were quantified by RiboGreen assay (Thermo) using the manufacturer's protocol,
479 subjected to library preparation as individual replicates (4sU-seq) or pooled replicates (APEX-seq).
480 Libraries were prepared with NEBNext Ultra II Directional RNA library prep Kit (NEB#E7760)
481 and NEBNext rRNA Depletion Kit (NEB#E6310) using the manufacturer's protocol.

482

483 **eCLIP-seq**

484 Cells cultured in the absence or presence of etoposide were washed in PBS, subjected to UV
485 irradiation (200 mJ/cm²), scraped, resuspended in cold PBS, pelleted (1200 rpm, 5 min) and stored
486 at -80°C. The pellets were lysed (20 min, 4°C) in eCLIP lysis buffer (50 mM tris-HCl pH7.4,
487 150 mM NaCl, 1 mM EDTA, 1% NP-40, 0.5% sodium deoxycholate, 0.25 mM TCEP). After
488 limited RNaseI (Invitrogen) and TURBO DNase (Invitrogen) digestion (20 min, 37°C), 5 µg
489 NONO antibody was coupled to 30 µL protein G dynabeads and incubated with lysates (4°C,
490 overnight). The samples were washed in eCLIP lysis buffer, in wash buffer (50 mM tris-HCl pH7.4,
491 300 mM NaCl, 1 mM EDTA, 1% NP-40, 0.5% sodium deoxycholate, 0.25 mM TCEP), followed
492 by two washes in low-salt wash buffer (50 mM tris-HCl pH7.4, 1 mM EDTA, 0.5% NP-40).
493 Subsequent library preparation was performed as described (Van Nostrand 2016).

494

495 **Imaging**

496 Cells grown on cover slips (Roth) were washed in PBS, fixed (10 min) in 3% paraformaldehyde
497 (Sigma), washed in PBS, permeabilised with PBS/0.1% triton x-100 (10 min) and blocked with
498 PBS/10% FBS (2 h, 4°C). Primary and secondary antibodies (Supplemental Table S3) were diluted
499 in PBS/0.15% FBS and incubated in a humidified chamber (overnight, 4°C or 2 h, RT),
500 respectively. Cells were washed between incubations with PBS/0.1% triton x-100, sealed in 6-

501 diamidino-2-phenylindole (DAPI)-containing mounting medium (Vectashield), and imaged by
502 confocal microscopy (Leica-SP2, 63x, airy=1, sequential acquisition between frames, equal
503 exposure times). Pan-nuclear localisation was scored in cells that display homogenous nuclear
504 staining and colocalisation with nucleolar markers based on RGB profiler and Pearson's correlation
505 coefficient (ImageJ). PLAs were performed with a Duolink in-situ PLA kit (Sigma) using the
506 manufacturer's protocol. RNA-FISH experiments employ 30 non-overlapping, Quasar570-labeled
507 sense DNA probes reverse complementary to 0.6 kb of the mapped region of antisense transcription
508 at IGS-22 (Stellaris probe designer, masking level ≥ 2 , Biosearch, Supplemental Table S7) using
509 the manufacturer's protocol.

510

511 **Statistics and bioinformatics**

512 For APEX-seq, CUT&RUN-seq and 4sU-seq, base calling was performed with Illumina's FASTQ
513 Generation software v1.0.0 and quality was tested by FastQC. Reads were mapped with STAR
514 (4sU-seq) (Dobin et al. 2013) or Bowtie2 (Langmead and Salzberg 2012) (other) to human hg19,
515 human T2T, mouse mm10 or *E.coli* genome. Mouse reads for spike-normalisation were used as
516 described (Orlando et al. 2014). CUT&RUN-seq read normalisation was performed by the sample-
517 wise division of hg19-mapped reads by *E.coli*-mapped reads or read depth. The ratio was multiplied
518 with the smallest number of *E.coli*-mapped reads. For 4sU-seq, reads falling in introns were
519 considered, spike-normalised, sorted and indexed with SAMtools. Bedgraph files were generated
520 with the genomecov function from BEDTools (Quinlan and Hall 2010). Density files were
521 visualised by Integrated Genome Browser (IGB).

522 CUT&RUN-seq density plots were generated with ngs.plot using normalised bam files,
523 testing top 1000 expressed genes in U2OS (Lorenzin et al. 2016). 1% extreme values were trimmed
524 (option “-RB 0.01”). For APEX-seq, gene expression was assessed with featureCounts (Liao et al.

525 2014) on bam files with intron-containing, non-spliced reads. Differential gene expression was
526 assessed with edgeR (Galaxy) using Benjamini Hochberg p-value <0.05, rejecting genes with <100
527 counts, and excluding non/weakly expressed genes. For 4sU-seq, counts that overlap between the
528 spike normalised bam files and Human Genes (GRCh37.p13) were assessed with bedtool Intersect
529 intervals (Galaxy), testing top 1000 expressed genes in U2OS (Lorenzin et al. 2016). The read
530 count mapped reads for each condition were used for scatter plots in GraphPad.

531 For mapping of mNET-seq data to rDNA loci, FASTQ files were aligned to a custom
532 reference genome based on U13369.1. Alignment was performed with bowtie2 allowing 1
533 mismatch and aligned reads were normalised to the sample with minimum aligned reads. Aligned
534 reads were converted into bedGraphs carrying equal number of reads in the rDNA region and
535 visualised by IGB. For analysis of IGS loci, paired-end samples were mapped to human genome
536 CHM13 (version 1.1) with bowtie2 an preset parameter “very-sensitive-local”, and normalised to
537 spiked-in reads mapping to mm10. A bed file with the coordinates of 214 rDNA-IGS (arranged in
538 5 clusters) was extracted from the gff3-file for CHM13 draft annotation v1.1, and used to generate
539 a multifasta file with 6.8 million nucleotides. 470 *Alu* repeat sequences (representing 50 sub-
540 families) were derived from hg38, with coordinates from the rmsk-table at UCSC (total length
541 112.000bp). IGS sequences not matching *Alu* elements were identified with blastn, resulting in 6.3
542 million nucleotides of “non-*Alu*” IGS, which were divided into bins of 100 nt. The number of spike-
543 normalised ChIPseq reads mapping to each bin was determined with bedtools intersect. Numbers
544 for bins overlapping individual IGSs were pooled.

545 BLISS-seq samples were demultiplexed based on their condition-specific barcodes with
546 UMI-tools, allowing 1 mismatch, separately mapped to hg19 using Bowtie2 (default parameters)
547 and filtered against an ENCODE Blacklist file to remove regions of high variance with bedtools
548 intersect. For quantification of DSBs duplicated reads were identified by UMI, grouped and

549 deduplicated with UMI-tools (default parameters). Density profiles were generated by R (package
550 metagene2, assay parameter ‘ChIPseq’, 200 bp read extension). Bar graph was generated with by
551 R (package exomeCopy) in the respective regions up- and downstream of the annotated TSS and
552 divided by the number of genes in the corresponding gene set. Publicly available RNA-seq data
553 (ENCODE: ENCFF182XEY) were filtered by gene length (≥ 1500 bp) to stratify genes by
554 expression into highly (FPKM > 10) and lowly (FPKM ≤ 1) expressed genes. Promoters with
555 proximal downstream TSSs were removed.

556 Paired-end sequencing reads from eCLIP experiments were trimmed with a custom Python
557 script to identify the UMI and aligned to hg38 with the Burrows–Wheeler Aligner (BWA). PCR
558 duplicates were removed by Picard’s MarkDuplicates with UMI-aware deduplication. Enriched
559 protein-binding regions were identified by MACS2 callpeak (parameters ‘-g hs -s 58 -B --keep-
560 dup all --nomodel --extsize 50 --d-min 5 --scale-to small –B’, comparing IP and size-matched IN
561 samples). Visualisations of regions were rendered from the PCR-deduplicated .bam files by IGB.
562 Distribution analysis employed ChIPpeakAnno package and
563 TxDb.Hsapiens.UCSC.hg38.knownGene dataset, with plot generated using ggplot2.
564

565 **Data availability**

566 NGS data are available at the gene expression omnibus (accession number GSE233594).

567

568 **Competing interests**

569 The authors declare no competing interests.

570

571 **Acknowledgments**

572 We acknowledge Martin Eilers for feedback and Cato Stoffer for technical support. Funding was
573 provided by the German Cancer Aid, Mildred-Scheel Early Career Center for Cancer Research,
574 grant 8606100-NG1 (K.B.), the German Research Foundation, grant BA 7941/1-1 (A.B.), the
575 European Research Council, grant TarMyc (E.W.) and the Helmholtz Young Investigator Group
576 programme (M.M.). This publication was supported by the Open Access Publication Fund of the
577 University of Würzburg.

578 Author contributions: B.T. and K.B. conceived the project and performed the bulk of experiments.
579 V.M. performed immunoblotting and imaging. G.C., J.H., P.B., C.P.A. and S.G. supported library
580 preparations; G.C., A.B., Y.W., C.P.A., D.S. and P.G. performed bioinformatic analysis. E.W.,
581 M.M., and K.B. supervised the project. B.T. and K.B. wrote the draft. K.B. finalised the
582 manuscript.

583

584 REFERENCES

585 Abraham KJ, Khosraviani N, Chan JNY, Gorthi A, Samman A, Zhao DY, Wang M, Bokros M,
586 Vidya E, Ostrowski LA, Oshidari R, Pietrobon V, Patel PS, Algouneh A, Singhania R,
587 Liu Y, Yerlici VT, De Carvalho DD, Ohh M, Dickson BC, Hakem R, Greenblatt JF, Lee
588 S, Bishop AJR, Mekhail K. Nucleolar RNA polymerase II drives ribosome biogenesis.
589 *Nature*. 2020 Sep;585(7824):298-302. doi: 10.1038/s41586-020-2497-0. Epub 2020 Jul
590 15. PMID: 32669707; PMCID: PMC7486236.

591 Amelio AL, Miraglia LJ, Conkright JJ, Mercer BA, Batalov S, Cavett V, Orth AP, Busby J,
592 Hogenesch JB, Conkright MD. A coactivator trap identifies NONO (p54nrb) as a
593 component of the cAMP-signaling pathway. *Proc Natl Acad Sci U S A*. 2007 Dec
594 18;104(51):20314-9. doi: 10.1073/pnas.0707999105. Epub 2007 Dec 11. PMID:
595 18077367; PMCID: PMC2154428.

596 Bader AS, Bushell M. DNA:RNA hybrids form at DNA double-strand breaks in transcriptionally
597 active loci. *Cell Death Dis*. 2020 Apr 24;11(4):280. doi: 10.1038/s41419-020-2464-6.
598 PMID: 32332801; PMCID: PMC7181826.

599 Blackford AN, Jackson SP. ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA
600 Damage Response. *Mol Cell*. 2017 Jun 15;66(6):801-817. doi:
601 10.1016/j.molcel.2017.05.015. PMID: 28622525.

602 Burger K, Ketley RF, Gullerova M. Beyond the Trinity of ATM, ATR, and DNA-PK: Multiple
603 Kinases Shape the DNA Damage Response in Concert With RNA Metabolism. *Front Mol*
604 *Biosci.* 2019 Aug 2;6:61. doi: 10.3389/fmolb.2019.00061. PMID: 31428617; PMCID:
605 PMC6688092.

606 Ciccia A, Elledge SJ. The DNA damage response: making it safe to play with knives. *Mol Cell.*
607 2010 Oct 22;40(2):179-204. doi: 10.1016/j.molcel.2010.09.019. PMID: 20965415;
608 PMCID: PMC2988877.

609 Clouaire T, Rocher V, Lashgari A, Arnould C, Aguirrebengoa M, Biernacka A, Skrzypczak M,
610 Aymard F, Fongang B, Dojer N, Iacovoni JS, Rowicka M, Ginalski K, Côté J, Legube G.
611 Comprehensive Mapping of Histone Modifications at DNA Double-Strand Breaks
612 Deciphers Repair Pathway Chromatin Signatures. *Mol Cell.* 2018 Oct 18;72(2):250-
613 262.e6. doi: 10.1016/j.molcel.2018.08.020. Epub 2018 Sep 27. PMID: 30270107;
614 PMCID: PMC6202423.

615 D'Alessandro G, Whelan DR, Howard SM, Vitelli V, Renaudin X, Adamowicz M, Iannelli F,
616 Jones-Weinert CW, Lee M, Matti V, Lee WTC, Morten MJ, Venkitaraman AR, Cejka P,
617 Rothenberg E, d'Adda di Fagagna F. BRCA2 controls DNA:RNA hybrid level at DSBs
618 by mediating RNase H2 recruitment. *Nat Commun.* 2018 Dec 18;9(1):5376. doi:
619 10.1038/s41467-018-07799-2. PMID: 30560944; PMCID: PMC6299093.

620 Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras
621 TR. STAR: ultrafast universal RNA-seq aligner. *Bioinformatics.* 2013 Jan 1;29(1):15-21.
622 doi: 10.1093/bioinformatics/bts635. Epub 2012 Oct 25. PMID: 23104886; PMCID:
623 PMC3530905.

624 Dutertre M, Lambert S, Carreira A, Amor-Guérat M, Vagner S. DNA damage: RNA-binding
625 proteins protect from near and far. *Trends Biochem Sci.* 2014 Mar;39(3):141-9. doi:
626 10.1016/j.tibs.2014.01.003. Epub 2014 Feb 14. PMID: 24534650.

627 Emili A, Shales M, McCracken S, Xie W, Tucker PW, Kobayashi R, Blencowe BJ, Ingles CJ.
628 Splicing and transcription-associated proteins PSF and p54nrb/nonO bind to the RNA
629 polymerase II CTD. *RNA.* 2002 Sep;8(9):1102-11. doi: 10.1017/s1355838202025037.
630 PMID: 12358429; PMCID: PMC1370324.

631 Fazal FM, Han S, Parker KR, Kaewsapsak P, Xu J, Boettiger AN, Chang HY, Ting AY. Atlas of
632 Subcellular RNA Localization Revealed by APEX-Seq. *Cell.* 2019 Jul 11;178(2):473-
633 490.e26. doi: 10.1016/j.cell.2019.05.027. Epub 2019 Jun 20. PMID: 31230715; PMCID:
634 PMC6786773.

635 Feng S, Manley JL. Beyond rRNA: nucleolar transcription generates a complex network of
636 RNAs with multiple roles in maintaining cellular homeostasis. *Genes Dev.* 2022 Aug
637 1;36(15-16):876-886. doi: 10.1101/gad.349969.122. PMID: 36207140; PMCID:
638 PMC9575697.

639 Gómez-Cabello D, Pappas G, Aguilar-Morante D, Dinant C, Bartek J. CtIP-dependent nascent
640 RNA expression flanking DNA breaks guides the choice of DNA repair pathway. *Nat*

641 Commun. 2022 Sep 9;13(1):5303. doi: 10.1038/s41467-022-33027-z. PMID: 36085345;
642 PMCID: PMC9463442.

643 Hatchi E, Skourtis-Stathaki K, Venz S, Pinello L, Yen A, Kamieniarz-Gdula K, Dimitrov S,
644 Pathania S, McKinney KM, Eaton ML, Kellis M, Hill SJ, Parmigiani G, Proudfoot NJ,
645 Livingston DM. BRCA1 recruitment to transcriptional pause sites is required for R-loop-
646 driven DNA damage repair. Mol Cell. 2015 Feb 19;57(4):636-647. doi:
647 10.1016/j.molcel.2015.01.011. PMID: 25699710; PMCID: PMC4351672.

648 Iannelli F, Galbiati A, Capozzo I, Nguyen Q, Magnuson B, Michelini F, D'Alessandro G,
649 Cabrini M, Roncador M, Francia S, Crosetto N, Ljungman M, Carninci P, d'Adda di
650 Fagagna F. A damaged genome's transcriptional landscape through multilayered
651 expression profiling around in situ-mapped DNA double-strand breaks. Nat Commun.
652 2017 May 31;8:15656. doi: 10.1038/ncomms15656. PMID: 28561034; PMCID:
653 PMC5499205.

654 Jaafar L, Li Z, Li S, Dynan WS. SFPQ•NONO and XLF function separately and together to
655 promote DNA double-strand break repair via canonical nonhomologous end joining.
656 Nucleic Acids Res. 2017 Feb 28;45(4):1848-1859. doi: 10.1093/nar/gkw1209. PMID:
657 27924002; PMCID: PMC5605232.

658 Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature. 2009
659 Oct 22;461(7267):1071-8. doi: 10.1038/nature08467. PMID: 19847258; PMCID:
660 PMC2906700.

661 Knott GJ, Bond CS, Fox AH. The DBHS proteins SFPQ, NONO and PSPC1: a multipurpose
662 molecular scaffold. Nucleic Acids Res. 2016 May 19;44(9):3989-4004. doi:
663 10.1093/nar/gkw271. Epub 2016 Apr 15. PMID: 27084935; PMCID: PMC4872119.

664 Korsholm LM, Gál Z, Nieto B, Quevedo O, Boukoura S, Lund CC, Larsen DH. Recent advances
665 in the nucleolar responses to DNA double-strand breaks. Nucleic Acids Res. 2020 Sep
666 25;48(17):9449-9461. doi: 10.1093/nar/gkaa713. PMID: 32857853; PMCID:
667 PMC7515731.

668 Krietsch J, Caron MC, Gagné JP, Ethier C, Vignard J, Vincent M, Rouleau M, Hendzel MJ,
669 Poirier GG, Masson JY. PARP activation regulates the RNA-binding protein NONO in
670 the DNA damage response to DNA double-strand breaks. Nucleic Acids Res. 2012 Nov
671 1;40(20):10287-301. doi: 10.1093/nar/gks798. Epub 2012 Aug 31. PMID: 22941645;
672 PMCID: PMC3488241.

673 Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods. 2012 Mar
674 4;9(4):357-9. doi: 10.1038/nmeth.1923. PMID: 22388286; PMCID: PMC3322381.

675 Li J, Yan S. Molecular mechanisms of nucleolar DNA damage checkpoint response. Trends Cell
676 Biol. 2023 Mar 4:S0962-8924(23)00022-3. doi: 10.1016/j.tcb.2023.02.003. Epub ahead of
677 print. PMID: 36933998.

678 Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning
679 sequence reads to genomic features. *Bioinformatics*. 2014 Apr 1;30(7):923-30. doi:
680 10.1093/bioinformatics/btt656. Epub 2013 Nov 13. PMID: 24227677.

681 Lorenzin F, Benary U, Baluapuri A, Walz S, Jung LA, von Eyss B, Kisker C, Wolf J, Eilers M,
682 Wolf E. Different promoter affinities account for specificity in MYC-dependent gene
683 regulation. *Elife*. 2016 Jul 27;5:e15161. doi: 10.7554/elife.15161. PMID: 27460974;
684 PMCID: PMC4963202.

685 Machour FE, Ayoub N. Transcriptional Regulation at DSBs: Mechanisms and Consequences.
686 *Trends Genet*. 2020 Dec;36(12):981-997. doi: 10.1016/j.tig.2020.01.001. Epub 2020 Jan
687 28. PMID: 32001024.

688 Mamontova V, Trifault B, Boten L, Burger K. Commuting to Work: Nucleolar Long Non-
689 Coding RNA Control Ribosome Biogenesis from Near and Far. *Noncoding RNA*. 2021
690 Jul 14;7(3):42. doi: 10.3390/ncrna7030042. PMID: 34287370; PMCID: PMC8293466.

691 Mamontova V, Trifault B, Boten L, Burger K. Commuting to Work: Nucleolar Long Non-
692 Coding RNA Control Ribosome Biogenesis from Near and Far. *Noncoding RNA*. 2021
693 Jul 14;7(3):42. doi: 10.3390/ncrna7030042. PMID: 34287370; PMCID: PMC8293466.

694 Michelini F, Jalihal AP, Francia S, Meers C, Neeb ZT, Rossiello F, Gioia U, Aguado J, Jones-
695 Weinert C, Luke B, Biamonti G, Nowacki M, Storici F, Carninci P, Walter NG, d'Adda
696 di Fagagna F. From "Cellular" RNA to "Smart" RNA: Multiple Roles of RNA in Genome
697 Stability and Beyond. *Chem Rev*. 2018 Apr 25;118(8):4365-4403. doi:
698 10.1021/acs.chemrev.7b00487. Epub 2018 Mar 30. PMID: 29600857; PMCID:
699 PMC7717669.

700 Moore HM, Bai B, Boisvert FM, Latonen L, Rantanen V, Simpson JC, Pepperkok R, Lamond
701 AI, Laiho M. Quantitative proteomics and dynamic imaging of the nucleolus reveal
702 distinct responses to UV and ionizing radiation. *Mol Cell Proteomics*. 2011
703 Oct;10(10):M111.009241. doi: 10.1074/mcp.M111.009241. Epub 2011 Jul 21. PMID:
704 21778410; PMCID: PMC3205868.

705 Orlando DA, Chen MW, Brown VE, Solanki S, Choi YJ, Olson ER, Fritz CC, Bradner JE,
706 Guenther MG. Quantitative ChIP-Seq normalization reveals global modulation of the
707 epigenome. *Cell Rep*. 2014 Nov 6;9(3):1163-70. doi: 10.1016/j.celrep.2014.10.018. Epub
708 2014 Oct 30. PMID: 25437568.

709 Petti E, Buemi V, Zappone A, Schillaci O, Broccia PV, Dinami R, Matteoni S, Benetti R,
710 Schoeftner S. SFPQ and NONO suppress RNA:DNA-hybrid-related telomere instability.
711 *Nat Commun*. 2019 Mar 1;10(1):1001. doi: 10.1038/s41467-019-08863-1. PMID:
712 30824709; PMCID: PMC6397292.

713 Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features.
714 *Bioinformatics*. 2010 Mar 15;26(6):841-2. doi: 10.1093/bioinformatics/btq033. Epub
715 2010 Jan 28. PMID: 20110278; PMCID: PMC2832824.

716 Shao W, Bi X, Pan Y, Gao B, Wu J, Yin Y, Liu Z, Peng M, Zhang W, Jiang X, Ren W, Xu Y,
717 Wu Z, Wang K, Zhan G, Lu JY, Han X, Li T, Wang J, Li G, Deng H, Li B, Shen X. Phase
718 separation of RNA-binding protein promotes polymerase binding and transcription. *Nat*
719 *Chem Biol.* 2021 Dec 16. doi: 10.1038/s41589-021-00904-5. Epub ahead of print. PMID:
720 34916619.

721 Shav-Tal Y, Zipori D. PSF and p54(nrb)/NonO--multi-functional nuclear proteins. *FEBS Lett.*
722 2002 Nov 6;531(2):109-14. doi: 10.1016/s0014-5793(02)03447-6. PMID: 12417296.

723 Trifault B, Mamontova V, Burger K. In vivo Proximity Labeling of Nuclear and Nucleolar
724 Proteins by a Stably Expressed, DNA Damage-Responsive NONO-APEX2 Fusion
725 Protein. *Front Mol Biosci.* 2022 Jun 6;9:914873. doi: 10.3389/fmolb.2022.914873.
726 PMID: 35733943; PMCID: PMC9207311.

727 Van Nostrand EL, Pratt GA, Shishkin AA, Gelboin-Burkhart C, Fang MY, Sundararaman B,
728 Blue SM, Nguyen TB, Surka C, Elkins K, Stanton R, Rigo F, Guttman M, Yeo GW.
729 Robust transcriptome-wide discovery of RNA-binding protein binding sites with
730 enhanced CLIP (eCLIP). *Nat Methods.* 2016 Jun;13(6):508-14. doi: 10.1038/nmeth.3810.
731 Epub 2016 Mar 28. PMID: 27018577; PMCID: PMC4887338.

732 van Sluis M, McStay B. Nucleolar DNA Double-Strand Break Responses Underpinning rDNA
733 Genomic Stability. *Trends Genet.* 2019 Oct;35(10):743-753. doi:
734 10.1016/j.tig.2019.07.001. Epub 2019 Jul 25. PMID: 31353047.

735 Wang YL, Zhao WW, Bai SM, Ma Y, Yin XK, Feng LL, Zeng GD, Wang F, Feng WX, Zheng
736 J, Wang YN, Zeng B, Liu Q, Hung MC, Wan XB. DNA damage-induced paraspeckle
737 formation enhances DNA repair and tumor radioresistance by recruiting ribosomal protein
738 P0. *Cell Death Dis.* 2022 Aug 16;13(8):709. doi: 10.1038/s41419-022-05092-1. PMID:
739 35974014; PMCID: PMC9381602.

740 Wei Y, Luo H, Yee PP, Zhang L, Liu Z, Zheng H, Zhang L, Anderson B, Tang M, Huang S, Li
741 W. Paraspeckle Protein NONO Promotes TAZ Phase Separation in the Nucleus to Drive
742 the Oncogenic Transcriptional Program. *Adv Sci (Weinh).* 2021 Dec;8(24):e2102653.
743 doi: 10.1002/advs.202102653. Epub 2021 Oct 29. PMID: 34716691; PMCID:
744 PMC8693076.

745 Wu T, Lyu R, He C. spKAS-seq reveals R-loop dynamics using low-input materials by detecting
746 single-stranded DNA with strand specificity. *Sci Adv.* 2022 Dec 2;8(48):eabq2166. doi:
747 10.1126/sciadv.abq2166. Epub 2022 Nov 30. PMID: 36449625; PMCID: PMC9710868.

748 Xiao R, Chen JY, Liang Z, Luo D, Chen G, Lu ZJ, Chen Y, Zhou B, Li H, Du X, Yang Y, San
749 M, Wei X, Liu W, Lécyuer E, Graveley BR, Yeo GW, Burge CB, Zhang MQ, Zhou Y, Fu
750 XD. Pervasive Chromatin-RNA Binding Protein Interactions Enable RNA-Based
751 Regulation of Transcription. *Cell.* 2019 Jun 27;178(1):107-121.e18. doi:
752 10.1016/j.cell.2019.06.001. PMID: 31251911; PMCID: PMC6760001.

753 Yang YS, Yang MC, Tucker PW, Capra JD. NonO enhances the association of many DNA-
754 binding proteins to their targets. *Nucleic Acids Res.* 1997 Jun 15;25(12):2284-92. doi:
755 10.1093/nar/25.12.2284. PMID: 9171077; PMCID: PMC146775.

756 Yasuhara T, Xing YH, Bauer NC, Lee L, Dong R, Yadav T, Soberman RJ, Rivera MN, Zou L.
757 Condensates induced by transcription inhibition localize active chromatin to nucleoli. *Mol*
758 *Cell*. 2022 Aug 4;82(15):2738-2753.e6. doi: 10.1016/j.molcel.2022.05.010. Epub 2022
759 Jun 2. PMID: 35662392; PMCID: PMC9357099.

760 Yokoyama M, Sasaki M, Kobayashi T. Spt4 promotes cellular senescence by activating non-
761 coding RNA transcription in ribosomal RNA gene clusters. *Cell Rep*. 2023 Jan
762 10;42(1):111944. doi: 10.1016/j.celrep.2022.111944. Epub ahead of print. PMID:
763 36640349.

764 Zhang S, Cooper JA, Chong YS, Naveed A, Mayoh C, Jayatilleke N, Liu T, Amos S, Kobelke S,
765 Marshall AC, Meers O, Choi YS, Bond CS, Fox AH. NONO enhances mRNA processing
766 of super-enhancer-associated GATA2 and HAND2 genes in neuroblastoma. *EMBO Rep*.
767 2022 Nov 23:e54977. doi: 10.15252/embr.202254977. Epub ahead of print. PMID:
768 36416237.

769 Zong D, Oberdoerffer P, Batista PJ, Nussenzweig A. RNA: a double-edged sword in genome
770 maintenance. *Nat Rev Genet*. 2020 Nov;21(11):651-670. doi: 10.1038/s41576-020-0263-
771 7. Epub 2020 Aug 6. PMID: 32764716.

772

773

774 **FIGURE LEGENDS**

775 **Figure 1.** DNA damage induces RNAPII-dependent nucleolar transcripts in U2OS cells. (A)
776 Imaging (left) and quantitation (right) of HA-NONO variants and fibrillarin. Arrowhead,
777 colocalisation; R=Pearson correlation. n, number of cells. Each dot represents % of cells with pan-
778 nuclear HA signals as average from one acquisition. (B) Scheme of human ribosomal (r)DNA array
779 (~80 repeats on chr. 13, 14, 15, 21, 22). Intergenic spacer (IGS) 20 to 42, probe positions in kb
780 downstream of rDNA transcriptional start site (TSS). (C) Scatter plot displaying mNET-seq IGS
781 reads. (D) mNET-seq browser tracks for IGS consensus region 20-28 from inputs (IN, merged) or
782 after immunoprecipitation (IP) with CTD S2P-selective antibody \pm etoposide. Grey, *Alu* element;
783 green, induced region. (E) Imaging of GFP-NPM1 and Quasar570 RNA-FISH signals originating
784 at IGS-22. White box, zoom (left) and quantitation (right). n, number of cells. Each dot represents
785 % of cells with Quasar570-positive signals as average from two acquisitions. *, p-value <0.05 ; **,
786 p-value <0.001 ; two-tailed t-test; n.d., not detected. Error bar, mean \pm SD. Representative images
787 are shown.

788

789 **Figure 2.** R-loop formation and NONO IGS occupancy correlate with diNAR synthesis and NONO
790 nucleolar re-localisation in U2OS cells. (A) DRIP-qPCR using S9.6 antibody and region-specific
791 primers. (B) NONO ChIP using site-specific primers. (C) Imaging of NONO and V5-RNaseH1.
792 Arrowhead, pan-nuclear; #, nucleoplasmic signal. Broken circle, NONO signal in nucleolus (Nuc)
793 or nucleoplasm (NP). (D) NONO ChIP using site-specific primers. (E) Pull-down assay displaying
794 32P- γ -ATP end-labeled (32P*) gapmers by autoradiography after IP with immobilised HA-NONO
795 variants FL and Δ RRM1 and PAGE separation. Silver stain and immunoblot, loading controls;
796 dashed line, background: a.u. arbitrary units. *, p-value <0.05 ; **, p-value <0.001 ; two-tailed t-
797 test. Error bar, mean \pm SD. Representative images are shown. n=number of biological replicates.

798

799 **Figure 3.** DNA damage reduces promoter-associated occupancy of NONO and RNAPII activity
800 in U2OS cells. (A) Imaging (left) and quantitation (right) of proximity ligation assay (PLA) signals
801 for NONO/RNAPII or NONO/SPT5. Each dot represents one acquisition. n, number of cells; a.u.,
802 arbitrary units. (B) NONO CUT&RUN-seq at the transcriptional start site (TSS) of top 1000
803 expressed genes. Red, promoter region. (C) Browser tracks of NONO and histone H3 lys-4 tri-
804 methylation (H3K4me3) CUT&RUN-seq. Red, promoter region. (D) 4sU-seq read counts for the
805 gene body of 863 highly expressed genes. *, p-value <0.05; **, p-value <0.001; two-tailed t-test.
806 Error bar, mean \pm SD. Representative images are shown. n=number of biological replicates.

807

808 **Figure 4.** NONO mediates the nucleolar accumulation of transcripts in U2OS cells. (A) Schematic
809 displaying APEX-seq in U2OS:GFP-APEX2-NIK3 cells. StrAv, streptavidin; H₂O₂, hydrogen
810 peroxide. (B) Imaging of GFP and NONO in U2OS:GFP-APEX2-NIK3 cells. R=Pearson
811 correlation; n.d., not detected; arrowhead, pan-nuclear NONO. Representative images are shown.
812 (C) Immunoblots detecting NONO, SFPQ, PSPC1, GFP-APEX2-NIK3 and fibrillarin upon
813 incubation with biotin-phenol, H₂O₂ from whole cell lysates (WCL) or upon immunoselection with
814 streptavidin-coated beads. (D-F) Volcano plots displaying the relative abundance of transcripts as
815 ratios of reads. Red, overrepresented; blue, underrepresented; n=number of transcripts. (G) NONO
816 eCLIP-seq peak distribution genome-wide (left) and at the gene body (right). (H) Browser tracks
817 for NONO eCLIP-seq reads. Red, increased binding. (I) Browser tracks depicting V5-RNaseH1
818 CUT&RUN-seq reads for *CDKN1A* \pm NONO depletion/etoposide. Red box, region of increase.

819

820 **Figure 5.** Impairment of NONO interferes with DSB signaling in U2OS cells. (A) Immunoblots
821 detecting total ATM, pATM, pATM/ATR substrates, γ H2A.X, HA-NONO and endogenous

822 NONO. (B) BLISS-seq metagene profiles (left) and signal sum (right) detecting DSBs at the TSS
823 of highly and lowly expressed genes. Dashed line, background. (C) H2BK120ac CUT&RUN-seq
824 at TSSs of top 1000 expressed genes. *, p-value <0.05; **, p-value <0.001; two-tailed t-test. Error
825 bar, mean \pm SD. Representative images are shown. n=number of biological replicates. (D) Model
826 illustrating our findings.

827









